During the secondary analysis, the significantly less conservative but clinically meaningful criterion of secure response (outlined being a fifty% or more reduction in MADRS from baseline for 2 months) was used. On the patients who achieved steady reaction, 25.8% while in the esketamine group and 57.6% in the placebo group https://omarx011rhv9.plpwiki.com/user